Feature Channels:

Vision

Add to Favorites | Subscribe | Share

Filters:

  • (Press "esc" to clear)

Medicine

Channels:

David A. Solá-Del Valle, M.D., Joins Mass. Eye and Ear Glaucoma Service

DavidSolaDelValleheadshot.JPG

David A. Solá-Del Valle, M.D., a board-certified ophthalmologist and fellowship-trained glaucoma specialist, has recently joined the Glaucoma Service at Mass. Eye and Ear.

Medicine

Channels:

Janey L. Wiggs, M.D., Ph.D., FARVO, Receives ARVO Dr. David L. Epstein Award

WiggsPR.jpg

Janey L. Wiggs, M.D., Ph.D., FARVO, Associate Chief of Ophthalmology Clinical Research and Associate Director of the Howe Laboratory at Massachusetts Eye and Ear, is the 2018 recipient of the Dr. David L. Epstein Award

Medicine

Channels:

Glaucoma, Alzheimer's, Parkinson's Disease

Neurons Fight Back Early in Brain Disease

A therapeutic target to preserve vision in glaucoma patients could have treatment ramifications for age-related neurodegenerative disorders like Alzheimer’s and Parkinson’s, according to findings released today in the Proceedings of the National Academy of Sciences (PNAS).

Medicine

Science

Channels:

AI, Machine Learning, Ophthalmology, Infectious Disease, Pulmonology, Pneumonia, Pediatrics, Diagnostics and imaging, Retinal Diseases, convolutional neural network, Neural Networks

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 22-Feb-2018 12:00 PM EST

Medicine

Science

Channels:

eye, Glaucoma, Biology, Zebrafish, Blinding diseases

Research with Zebrafish May Lead to Treatment for Blinding Disorders, Including Glaucoma

ThinkstockPhotos-509053702.jpg

Jakub Famulski, an assistant professor of biology at the University of Kentucky, has received an R01 grant for over $1.8 million from the National Institutes of Health to study the early formation of the anterior segment of the eye, which includes the cornea, iris, ciliary muscle, drainage canals and pupil.

Science

Channels:

Cell Biology, Molecular Biology, Genetics, Opthalmalogy, Stem Cell, Drug Discovery

In Effort to Treat Rare Blinding Disease, Researchers Turn Stem Cells into Blood Vessels

Lin-ATF6-activated-hES-BV.jpg

People with a mutated ATF6 gene have a malformed or missing fovea, severely limiting vision. UC San Diego School of Medicine researchers first linked ATF6 to this type of vision impairment. Now the team discovered that a chemical that activates ATF6 converts patient stem cells into blood vessels.

Medicine

Channels:

Olympics, Neuroscience, Ed Connor

Media Tip Sheet: Making the Call and Giving Out the Gold: How Our Brains Judge Value in an Instant

OlympicTipSheetiStock-483918240.jpg

Medicine

Channels:

NEI Support Paved Early Pathway for Novel Glaucoma Therapies

The recent approval of two novel medications for glaucoma – the first new medications for the disorder in nearly 18 years – are fruit borne from decades of foundational scientific research supported by the National Eye Institute (NEI). The two medications, Vyzulta and Rhopressa, treat elevated eye pressure. High intraocular pressure is a causal risk factor for primary open-angle glaucoma, the most common form of glaucoma and a leading cause of vision loss and blindness in the U.S. and worldwide.

Medicine

Channels:

Glaucoma 360, Glaucoma Research Foundation, annual awards

Glaucoma Research Foundation to Honor Leaders in Glaucoma Innovation and Patient Care at 12th Annual Gala in San Francisco

The Catalyst Award, Glaucoma Research Foundation's highest honor, will be presented to Thomas W. Burns, President and CEO of Glaukos Corporation (Laguna Hills, CA), in recognition of his remarkable leadership and commitment to the development of innovative glaucoma treatments.

Medicine

Channels:

Glaucoma, glaucoma research, Glaucoma Research Foundation, Glaucoma 360

Glaucoma Research Foundation to Host the 7th Annual Glaucoma 360

Glaucoma Research Foundation will host the 7th Annual Glaucoma 360 from February 8th to February 10th in San Francisco. This signature three-day event highlights innovation in glaucoma to ensure patients have access to the latest and most effective treatment options.







Chat now!